Lee Cranmer, MD, PhD
Basic profileProfessor and Section Chief of Sarcoma Medical Oncology · City Of Hope National Medical Center
Lee Cranmer is Professor and Section Chief of Sarcoma Medical Oncology at City Of Hope National Medical Center. OpenAlex indexes 272 publications with 10,291 citations (h-index 42); ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Updated 23 Oct 2026
Lee Cranmer, MD, PHD, is Professor and Section Chief of Sarcoma Medical Oncology at City of Hope (Duarte, CA). The public record shows 272 publications with 10,308 citations (h-index 42), centered on Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 5 companies.
- Most recent indexed publication: 2025 · JCO precision oncology
- Top research focus: Sarcoma Diagnosis and Treatment
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 86.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Duarte Rd
Duarte, CA 91010-3012
Telephone
800-826-4673Provider last certified this registry record 16 Mar 2026 · collected 28 Jul 2026.
Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities
Sponsor: University of Washington
- Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Sponsor: Fred Hutchinson Cancer Center
- Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
Sponsor: University of Washington
Industry payments
Updated 23 Oct 2026
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SpringWorks Therapeutics, Inc.Program year20251 payment
- Deciphera Pharmaceuticals Inc.Program year20256 payments
- Aadi Bioscience, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
62.1%Factor Xa inhibitor62.1%Eliquis100%Part D<11 patientsSensory organs
37.9%Corticosteroid37.9%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Congress activity
Updated 23 Oct 2026
68 congress contributions (2006–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- An exploratory study of the potential clinical impact of ethnicity in patients with retroperitoneal sarcoma.
ASCO Annual Meeting
ASCO2026Co-author - Phase II pilot study of pembrolizumab (PEM) and neoadjuvant radiation therapy (nRT) in high-risk soft tissue sarcomas (STS).
ASCO Annual Meeting
ASCO2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets.
JCO precision oncology
Article2025 - Combined Germline and Mosaic SDHA Mutation Is Associated With a Multicancer Syndrome Including Neuroblastoma, Renal Cancer, and Multifocal GI Tumor.
JCO precision oncology
Case Report2024 - Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.
Journal of clinical oncology
Clinical Trial2024 - Incidence, demographics, and survival of malignant hemangioendothelioma in the United States.
Cancer medicine
Article2023 - Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406).
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaArticle2,640 citations2015
- 02
- 03
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lee-cranmer-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Physicians
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →binaytara.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Erminia Massarelli, MD
City Of Hope National Medical Center
Swetha Thiruvengadam, MD
City Of Hope National Medical Center
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”